A recent preclinical study conducted by Bolli et al. (2018) has shown that AX09‐0M6 VLPs derived from the bacteriophage MS2 can efficiently be used as a cancer vaccine platform in some aggressive forms of breast cancers, namely triple‐negative and HER‐2+ breast cancer. Here, ERBB2 is linked to breast carcinoma.